Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 26.8608
- Book/Share 19.5386
- PB 5.86
- Debt/Equity 0.815
- CurrentRatio 0.7941
- ROIC 0.1778
- MktCap 225029078945.0
- FreeCF/Share 7.5442
- PFCF 15.1565
- PE 17.4853
- Debt/Assets 0.3129
- DivYield 0.035
- ROE 0.3071
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Read More
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division Florent Cespedes - Societe Generale Cross Asset Research Harry Thomas d'Alton Sephton - Crédit Suisse AG, Research Division James Patrick Quigley - Goldman Sachs Group, Inc., Research Division Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - UBS Investment Bank, Research Division Michael Thomas Nedelcovych …
Read More
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.
Read More
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Read More
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.
Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Published: July 17, 2025 by: CNBC
Sentiment: Positive
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.
Read More
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Published: July 17, 2025 by: Reuters
Sentiment: Positive
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Read More
Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive Committee (ECN) After an extraordinary 22-year career at Novartis and more than 12 years as a member of the ECN, Harry Kirsch will retire and step down from the ECN on March 15, 2026 Basel, July 17, 2025 – Novartis announced today the appointment of Mukul Mehta as the Chief Financial Officer (CFO) and a member of the Executive Committee of Novartis (ECN), …
Read More
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income margin1 reached 42.2%, +340 basis points (cc), mainly driven by higher net sales Q2 operating income grew +25% (cc, +21% USD); net income up +26% (cc, +24% USD) Q2 core EPS 1 grew +24% (cc, +23% USD) to USD 2.42 Q2 free …
Read More
Novartis cannot block generic version of Entresto, judge rules
Published: July 16, 2025 by: Reuters
Sentiment: Negative
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.
Read More
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Read More
Why Novartis Is Still A 'Buy' After 15% Surge
Published: July 13, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Trump's hot take toward the pharmaceutical industry and his hard stance on U.S. trading partners, Novartis' share price continues to rise. The main contributors to maintaining bullish sentiment towards the Swiss pharmaceutical behemoth are the strong performance of its cardiovascular, oncology, and immunology franchises. For example, sales of its blockbuster Cosentyx amounted to $1.53 billion in the first three months of 2025, up 15.7% year-on-year.
Read More
Novartis loses bid to block US Entresto generic through 2026
Published: July 11, 2025 by: Reuters
Sentiment: Negative
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
Read More
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.
Read More
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Final Trades: Novartis, Sixth Street, Amazon and the IYF
Published: June 26, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Novartis completes acquisition of Regulus Therapeutics
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
As markets reel under the Israel-Iran conflict, NVS, ENSG, MTZ, BILI and STRL stocks offer a safer path through volatility.
Read More
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novartis (NVS) Could Be a Great Choice
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Published: June 02, 2025 by: Reuters
Sentiment: Positive
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered.
Read More
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Published: June 02, 2025 by: WSJ
Sentiment: Positive
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Read More
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, …
Read More
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883